NA-Semax Amidate vs Davunetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-Acetyl Semax Amidate, NA-Semax
NA-Semax Amidate is the stabilized form of Semax, the Russian nootropic peptide derived from a fragment of ACTH. Same modification logic as the Selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. It is the most widely used Semax variant in Western nootropic circles, largely on the strength of that stability argument.
Also: NAP, AL-108
Davunetide (NAP) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP), discovered at Tel Aviv University and given as a nasal spray. It was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. Its big test, a phase 2/3 trial in progressive supranuclear palsy (PSP), failed cleanly in 2012, and development stalled. It has since been revived by its inventors, who argue it works in women and are pursuing ADNP syndrome, but those claims rest on reanalyses of old data, not a new successful trial.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | NA-Semax Amidate | Davunetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is a synthetic analog of ACTH (4-10), a fragment of adrenocorticotropic hormone that has been stripped of hormonal activity while retaining effects on the brain. Its best-characterized action is a marked increase in BDNF and NGF expression in the hippocampus, which is the mechanistic basis for the memory and neuroprotection claims. It also modulates dopaminergic and serotonergic transmission, and affects the melanocortin system, which is thought to contribute to its effects on attention and motivation. Notably it does this without the HPA axis activation you would expect from something derived from ACTH, because the fragment lacks the region responsible for that. The acetylation and amidation slow degradation by peptidases, so more of the dose survives to act. | NAP comes from ADNP, a protein essential for brain development. In cell and animal studies it interacts with microtubule end-binding proteins (EB1 and EB3), promoting microtubule stability and reducing tau phosphorylation, which is why it was aimed at tauopathies like PSP and Alzheimer's disease. Mutations in the ADNP gene itself cause ADNP syndrome (Helsmoortel-Van der Aa syndrome), and in ADNP-deficient mice NAP improved some behavioral and neural measures, the rationale for that newer program. The PSP trial did not include target-engagement measures, so it never showed the drug was actually doing this in human brains. |
| Common Dosing | 300-600 mcg daily Once or twice daily, morning and early afternoon | 30 mg intranasal twice daily (PSP trial dose) Once or twice daily |
| Administration | Intranasal is the standard and best-supported route, since it was developed as a nasal formulation | Intranasal spray (an IV form, AL-208, was tested in cardiac surgery) |
| Typical Duration | Community protocols commonly report 2-4 week blocks | 12 weeks to 52 weeks in trials |
| Best Time to Take | Morning, or morning and early afternoon if split | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Semax has a genuine and reasonably large research base, concentrated in Russia, where it is a registered medicine used for ischemic stroke, cognitive impairment and optic nerve disorders. Animal work consistently supports the BDNF and NGF upregulation, and there is human clinical work in stroke recovery. The important caveat is the same as for Selank: this literature is largely Russian, much of it predates modern trial standards, replication in large Western randomized trials has not happened, and neither the FDA nor the EMA has assessed it. For the amidate variant specifically there is no independent published pharmacology comparing it to standard Semax in humans. The stability modification is chemically sound and widely used, and the assumption that it improves real-world effect is reasonable but unproven. | The headline result is negative. In the phase 2/3 PSP trial (Boxer and colleagues, Lancet Neurology 2014), 313 patients got 30 mg intranasal davunetide twice daily or placebo for 52 weeks. Disease progression was identical in both groups on both primary measures (PSP Rating Scale and Schwab and England daily living scale), and the authors concluded davunetide is not an effective treatment for PSP. Earlier phase 2 work was mixed: a 12-week trial in 144 people with amnestic mild cognitive impairment hinted at working-memory benefits, and a schizophrenia trial missed one co-primary endpoint while hitting another. The original developer, Allon Therapeutics, stopped investing and was later absorbed by Paladin Labs. The revival comes from the inventor's group: post hoc reanalyses of the PSP data (Translational Psychiatry 2023, Molecular Psychiatry 2026) report that women declined faster than men and that davunetide slowed decline in women only. A similar sex-split reanalysis of the MCI trial was published in 2024. These findings are interesting but are subgroup analyses of trials that failed overall, done by researchers tied to the company now developing the drug (ExoNavis Therapeutics), so they need a new prospective trial to mean much. ExoNavis has said a phase 3 in children with ADNP syndrome began in 2024, but Alzforum could not find it in trial registries. Davunetide holds FDA orphan and rare pediatric disease designations and EMA orphan status for ADNP syndrome. |
Frequently Asked Questions: NA-Semax Amidate vs Davunetide
What is the difference between NA-Semax Amidate and Davunetide?
NA-Semax Amidate is a cognitive peptide that na-semax amidate is the stabilized form of semax, the russian nootropic peptide derived from a fragment of acth. same modification logic as the selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. it is the most widely used semax variant in western nootropic circles, largely on the strength of that stability argument. Davunetide is a cognitive peptide that davunetide (nap) is an eight-amino-acid fragment (napvsipq) of activity-dependent neuroprotective protein (adnp), discovered at tel aviv university and given as a nasal spray. it was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. its big test, a phase 2/3 trial in progressive supranuclear palsy (psp), failed cleanly in 2012, and development stalled. it has since been revived by its inventors, who argue it works in women and are pursuing adnp syndrome, but those claims rest on reanalyses of old data, not a new successful trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, NA-Semax Amidate or Davunetide?
Neither is universally "better" - the choice depends on your specific goals. NA-Semax Amidate is typically used for cognitive purposes, while Davunetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can NA-Semax Amidate and Davunetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using NA-Semax Amidate and Davunetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.